DOCGO INC Stock Price, News & Analysis

DocGo (NASDAQ: DCGO) will report its Q1 results for the period ending March 31, 2022, on May 9, 2022, after market close. An investor conference call is scheduled for May 10, 2022, at 8:30 AM ET. DocGo specializes in last-mile mobile health services and integrated medical transportation, aiming to modernize healthcare delivery. The company highlights its innovative technology and certified professionals that enhance patient care and operational efficiency. Investors can access the call details and webcast through the company's investor relations page.

DocGo has partnered with Jefferson Health to transport the first patient using an all-electric, zero-emissions ambulance, marking a significant milestone in sustainable healthcare solutions. This vehicle, registered as the first of its kind in the U.S., is designed to be 1/10th as polluting as traditional gasoline ambulances. The electric ambulance will begin regular patient transports and is part of DocGo's goal to establish an all-electric fleet by 2032. The collaboration, ongoing since May 2019, aims to improve mobile medical care delivery in the U.S.

DocGo, a leader in mobile health services, will showcase its all-electric, zero-emissions ambulance at the New York International Auto Show from April 15-24, 2022. This innovative ambulance emits only 10% of the pollutants of traditional models, aligning with the company’s commitment to sustainability. DocGo aims for an all-electric fleet by 2032. This exhibition provides an opportunity for attendees to engage with representatives and learn about the future of eco-friendly medical transportation, part of the show's focus on electric vehicles.

DocGo (NASDAQ: DCGO), a leader in last-mile mobile health services, announced that CEO Stan Vashovsky and CFO Andre Oberholzer will present at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, at 4:30 PM Eastern Time. The event will be accessible via a webcast on the investor relations section of DocGo’s website. DocGo aims to enhance patient care through its integrated medical mobility solutions, bridging physical and virtual healthcare delivery.

DocGo (NASDAQ: DCGO) announces significant growth in the UK through its subsidiary, Ambulnz Community Partners, which has secured three new contracts. These contracts will facilitate the expansion of services into new territories, including East and Central England and Greater Manchester. This initiative aims to enhance patient access to medical transportation, including emergency services and maternity transfers. The company is committed to delivering high-quality healthcare and expanding its international footprint.

DocGo is set to host a fireside chat on March 30, 2022, at 2:00 PM ET, featuring key customers Carnival Corporation and Thomas Jefferson University. The event, moderated by Steve Halper from LifeSci Advisors, will include discussions on mobile health services and how DocGo enhances care quality while reducing costs. Participants include Javonte Anyabwele from Carnival and Dr. Judd E. Hollander from Thomas Jefferson University. A Q&A session will follow the discussion. Register for the event here.

DocGo (NASDAQ:DCGO) reported remarkable financial results for Q4 and the full year ending December 31, 2021. Q4 revenue soared to $121.3 million, up 289% from $31.2 million the previous year. For the full year, revenue reached $318.7 million, a 239% increase from $94.1 million in 2020. The company achieved positive adjusted EBITDA of $17.3 million in Q4 and $25.1 million for the year, alongside net income of $20.3 million in Q4.

DocGo announced impressive financial results for Q4 2021 and the full year, showcasing a 289% increase in quarterly revenue ($121.3M) and a 239% rise in annual revenue ($318.7M) compared to 2020. Positive adjusted EBITDA was reported at $17.3M for Q4 and $25.1M for the full year, with a substantial turnaround to net income of $20.3M in Q4 from a loss the previous year. The company has a strong cash position of $175.5M and expects 2022 revenue to grow 27-32% over 2021, despite non-recurring Covid testing revenue.